X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The phase 3 ENGOT-ov50 / GOG-3029 / INNOVATE-3 clinical trial of Tumor Treating Fields (TTFields) together with paclitaxel in patients with platinum-resistant ovarian cancer did not meet its primary endpoint of overall survival (OS) at -the final analysis.
Lead Product(s): NovoTTF-100L,Paclitaxel
Therapeutic Area: Oncology Product Name: NovoTTF-100L
Highest Development Status: Phase IIIProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 28, 2023
Details:
Gemcitabine (delivered via NovoTTF-200T device) is a cytotoxic agent, its metabolite dFdCDP inhibits ribonucleoside reductase (RR), an enzyme regulating DNA biosynthesis via controlling the formation of nucleoside triphosphates (NTPs). It is approved for various solid tumours.
Lead Product(s): Gemcitabine,Paclitaxel
Therapeutic Area: Oncology Product Name: NovoTTF-200T
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 15, 2023
Details:
The primary endpoint is superior overall survival of patients treated with TTFields plus immune checkpoint inhibitors or NovoTTF-200T (Docetaxel) versus immune checkpoint inhibitors or docetaxel alone.
Lead Product(s): Docetaxel
Therapeutic Area: Oncology Product Name: NovoTTF-200T
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 05, 2023
Details:
KEYNOTE-B36 is designed to evaluate the safety and effectiveness of Tumor Treating Fields together with KEYTRUDA® (pembrolizumab), anti-PD-1 therapy, for the first-line treatment of locally advanced or metastatic intrathoracic non-small cell lung cancer that expresses PD-L1.
Lead Product(s): Pembrolizumab
Therapeutic Area: Oncology Product Name: Keytruda
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 21, 2022
Details:
Novocure and MSD plan to conduct a double-blind, placebo-controlled study of TTFields concomitant with KEYTRUDA and maintenance temozolomide (TMZ) versus TTFields together with placebo and maintenance TMZ for the treatment of adult patients with newly diagnosed GBM.
Lead Product(s): Pembrolizumab,Temozolomide
Therapeutic Area: Oncology Product Name: Keytruda
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: MSD Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 26, 2022
Details:
The phase III trial aimed to test the efficacy and safety of Tumor Treating Fields (TTFields) in combination with gemcitabine and nab-paclitaxel, for front line treatment of locally-advanced pancreatic adenocarcinoma.
Lead Product(s): Gemcitabine,Paclitaxel
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 08, 2022
Details:
Patients in phase 2 pilot trial 2-THE-TOP of tumor treating fields (TTFields) together with pembrolizumab and temozolomide, showed median progression-free survival of 12.1 months compared with 7.9 months for matched-control patients from EF-14.
Lead Product(s): Temozolomide,Pembrolizumab
Therapeutic Area: Oncology Product Name: Temodar
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 24, 2022
Details:
The primary endpoint of INNOVATE-3 is overall survival for drug-device combination of NovoTTF-100L(O) Tumor Treating Fields and Taxol (paclitaxel), The INNOVATE-3 study is designed to evaluate safety and effectiveness of TTFields together with paclitaxel in ovarian cancer.
Lead Product(s): Paclitaxel
Therapeutic Area: Oncology Product Name: Taxol
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 23, 2022
Details:
The phase 2 pilot 2-THE-TOP clinical study, evaluating the use of TTFields therapy together with the anti-PD-1 therapy (pembrolizumab) and chemotherapy (temozolomide) for the treatment of newly diagnosed GBM in 25 patients.
Lead Product(s): Temozolomide,Pembrolizumab
Therapeutic Area: Oncology Product Name: Temodar
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 24, 2022
Details:
Updated data from the phase 2 pilot 2-THE-TOP trial enables synergies between TTFields and immunotherapy agents, particularly pembrolizumab and temozolomide, and median progression-free survival was at least 11.2 months in patients with greater than 9 months of follow-up.
Lead Product(s): Temozolomide,Pembrolizumab
Therapeutic Area: Oncology Product Name: Temodar
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 15, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
